Delving into the Latest Updates on Beijing Colin Likang Medical Research Co., Ltd with Synapse

Overview

Tags

Immune System Diseases

Digestive System Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

PP2A(Protein phosphatase 2A)	1

? Primary objective To evaluate the safety and tolerability of single and multiple doses of IBD98-M sustained-release capsules in healthy adult subjects. ? Secondary objective To evaluate the pharmacokinetic (PK) characteristics of single and multiple doses of IBD98-M sustained-release capsules in healthy adult subjects.

Start Date-

Sponsor / Collaborator

Holy Stone Healthcare Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Colin Likang Medical Research Co., Ltd

Login to view more data

0 Patents (Medical) associated with Beijing Colin Likang Medical Research Co., Ltd

Login to view more data

100 Deals associated with Beijing Colin Likang Medical Research Co., Ltd

Login to view more data

100 Translational Medicine associated with Beijing Colin Likang Medical Research Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data